[HTML][HTML] Nivolumab plus ipilimumab versus sunitinib in advanced renal-cell carcinoma
RJ Motzer, NM Tannir, DF McDermott… - … England Journal of …, 2018 - Mass Medical Soc
Background Nivolumab plus ipilimumab produced objective responses in patients with
advanced renal-cell carcinoma in a pilot study. This phase 3 trial compared nivolumab plus …
advanced renal-cell carcinoma in a pilot study. This phase 3 trial compared nivolumab plus …
Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: extended follow-up of efficacy and safety results from a …
Background In the ongoing phase 3 CheckMate 214 trial, nivolumab plus ipilimumab
showed superior efficacy over sunitinib in patients with previously untreated intermediate …
showed superior efficacy over sunitinib in patients with previously untreated intermediate …
Cytoreductive nephrectomy in patients with synchronous metastases from renal cell carcinoma: results from the International Metastatic Renal Cell Carcinoma …
Background The benefit of cytoreductive nephrectomy (CN) for overall survival (OS) is
unclear in patients with synchronous metastatic renal cell carcinoma (mRCC) in the era of …
unclear in patients with synchronous metastatic renal cell carcinoma (mRCC) in the era of …
[HTML][HTML] Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended 4-year follow-up of the phase III CheckMate 214 …
L Albiges, NM Tannir, M Burotto, D McDermott… - ESMO open, 2020 - Elsevier
Purpose To report updated analyses of the phase III CheckMate 214 trial with extended
minimum follow-up assessing long-term outcomes with first-line nivolumab plus ipilimumab …
minimum follow-up assessing long-term outcomes with first-line nivolumab plus ipilimumab …
Nivolumab versus everolimus in patients with advanced renal cell carcinoma: updated results with long‐term follow‐up of the randomized, open‐label, phase 3 …
Background CheckMate 025 has shown superior efficacy for nivolumab over everolimus in
patients with advanced renal cell carcinoma (aRCC) along with improved safety and …
patients with advanced renal cell carcinoma (aRCC) along with improved safety and …
Conditional survival and long‐term efficacy with nivolumab plus ipilimumab versus sunitinib in patients with advanced renal cell carcinoma
Background Conditional survival estimates provide critical prognostic information for
patients with advanced renal cell carcinoma (aRCC). Efficacy, safety, and conditional …
patients with advanced renal cell carcinoma (aRCC). Efficacy, safety, and conditional …
Everolimus versus sunitinib for patients with metastatic non-clear cell renal cell carcinoma (ASPEN): a multicentre, open-label, randomised phase 2 trial
AJ Armstrong, S Halabi, T Eisen, S Broderick… - The Lancet …, 2016 - thelancet.com
Background Non-clear cell renal cell carcinomas are histologically and genetically diverse
kidney cancers with variable prognoses, and their optimum initial treatment is unknown. We …
kidney cancers with variable prognoses, and their optimum initial treatment is unknown. We …
Optimal sequencing of enzalutamide and abiraterone acetate plus prednisone in metastatic castration-resistant prostate cancer: a multicentre, randomised, open-label …
DJ Khalaf, M Annala, S Taavitsainen, DL Finch… - The Lancet …, 2019 - thelancet.com
Background Abiraterone acetate plus prednisone and enzalutamide are both used for the
treatment of metastatic castration-resistant prostate cancer. We aimed to determine the best …
treatment of metastatic castration-resistant prostate cancer. We aimed to determine the best …
Nivolumab (anti-PD-1; BMS-936558, ONO-4538) in combination with sunitinib or pazopanib in patients (pts) with metastatic renal cell carcinoma (mRCC).
5010 Background: Antiangiogenic agents sunitinib (S) and pazopanib (P) are SOC for
mRCC, but new therapies are needed as pts advance through therapy with limited survival …
mRCC, but new therapies are needed as pts advance through therapy with limited survival …
Metastatic non–clear cell renal cell carcinoma treated with targeted therapy agents: characterization of survival outcome and application of the International mRCC …
BACKGROUND This study aimed to apply the International mRCC Database Consortium
(IMDC) prognostic model in metastatic non–clear cell renal cell carcinoma (nccRCC). In …
(IMDC) prognostic model in metastatic non–clear cell renal cell carcinoma (nccRCC). In …